Compare Spotify Technology (SPOT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs GeneDx Holdings Corp — how do they compare? Spotify Technology trades at $529.16 (market cap $108.22B), while GeneDx Holdings Corp trades at $67.94 (market cap $2.02B). The key difference: Spotify Technology is far larger — about 53.6× GeneDx Holdings Corp's market cap, and Spotify Technology is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and GeneDx Holdings Corp for 19 Days on average.
| SPOT | WGS | |
|---|---|---|
Market Cap | $108.22B | $2.02B |
Volume | 1,655,796 | 734,640 |
Sector | Media | Health |
52-Week High | $692.04 | $167.51 |
52-Week Low | $412.75 | $34.51 |
Typical Hold Time | 111 Days | 19 Days |
Enterprise Value | $98.23B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $524.71, up 2.3% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income of $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains positive with 62% buy ratings and a $606.50 consensus price target.
The outlook remains favorable with continued revenue growth and margin expansion driving upside potential. Key risks include competitive pressures in streaming and market volatility. With strong institutional support and improving cash flow trends, SPOT presents a growth opportunity despite recent technical overbought conditions near resistance levels.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
